Global innovator in drug delivery platforms Lexaria
Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and
Drug Administration (“FDA”), for the first time ever, has authorized the
marketing of oral nicotine products through the Modified Risk Tobacco Product
pathway. According to the update, this pathway includes product categories that
could benefit from Lexaria’s technology. The FDA-authorized product format is
in the tobacco pouch category, similar to a mini tea-bag that is held in the
mouth from which the nicotine within is absorbed. Unlike chewing tobacco, there
is no need to spit. Significantly, because there is no combustion, heating or
vaporization of the tobacco pouch during use, as well as FDA-accepted
scientific evidence that included long-term epidemiological studies in association
with this approval, claims of a lower risk of mouth cancer, stroke, lung
disease, heart disease, emphysema and chronic bronchitis than cigarettes are
permitted by the FDA. “Lexaria applauds this informed and forward-looking
decision by the FDA to recognize improvements in delivery formats that are
being made by industry,” Lexaria Bioscience Corp. CEO Chris Bunka said in the
news release. “Lexaria realized long ago that DehydraTECH(TM) could empower
alternative nicotine product formats and as a result our delivery technology
which is already patented in the U.S. and patent pending around the world for
enhanced oral nicotine delivery.”
To view the full press releases, visit http://ibn.fm/l7EVp
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in
drug-delivery platforms. Its patented DehydraTECH(TM) drug-delivery technology
changes the way active pharmaceutical ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases
bio-absorption, reduces time of onset and masks unwanted tastes for orally
administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry
for use in cannabinoid beverages, edibles and oral products, as well as to a
world-leading tobacco producer for the development of smokeless, oral-based
nicotine products. Lexaria operates a licensed, in-house research laboratory
and holds a robust intellectual property portfolio with 16 patents granted and
over 60 patents pending worldwide. For more information, visit the company’s
website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
